ClinicalTrials.gov
ClinicalTrials.gov Menu

Diabetes Screening, Risk Management and Disease Management in a High-Risk Mental Health Population Part II

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00377117
Recruitment Status : Completed
First Posted : September 15, 2006
Last Update Posted : November 6, 2018
Sponsor:
Collaborators:
Eli Lilly and Company
St. Joseph's Health Care London
Information provided by (Responsible Party):
Lawson Health Research Institute

Brief Summary:
The purpose of this study is to learn more about the relationship between serious mental illness and the detection and management of diabetes and pre-diabetic conditions. Patients who have been diagnosed with schizophrenia are at an increased risk for developing diabetes and pre-diabetic conditions such as impaired glucose tolerance and impaired fasting glucose. In addition, novel antipsychotics have also been linked to impaired glucose metabolism and increased incidence of diabetes. The medical management of these patients may be difficult ot achieve through standard family practice. The objectives of this project are to: screen a sample of this high-risk population using an Oral Glucose Tolerance Test (OGTT), and to provide multidisciplinary team support to those identified as having diabetes or a pre-diabetic condition.

Condition or disease Intervention/treatment
Diabetes Mellitus Schizophrenia Psychotic Disorders Procedure: Management Procedure: Screening

  Show Detailed Description

Study Type : Observational
Actual Enrollment : 39 participants
Time Perspective: Other
Official Title: Diabetes Screening, Risk Management, and Disease Management in a High-Risk Mental Health Population.
Actual Study Start Date : May 2006
Actual Study Completion Date : July 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Mental Health





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients active in current Regional Mental Health Care London, Specialized Adult London Ambulatory Care and Assertive Community Treatment programs with known diagnosis of a Psychotic Disorder and/or use of Novel Antipsychotics.
  • Must have family physician contact and ability to consent to medical care.

Exclusion Criteria:

  • Any patient with declaration on file stating incapable of consenting to medical treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00377117


Locations
Canada, Ontario
Regional Mental Health Care London
London, Ontario, Canada, N6A 4H1
Sponsors and Collaborators
Lawson Health Research Institute
Eli Lilly and Company
St. Joseph's Health Care London
Investigators
Principal Investigator: Stewart B Harris, MD MPH CCFP FACPM Centre for Studies in Family Medicine
Principal Investigator: David RS Haslam, MSc MD FRCPC St. Joseph's Health Care London

Publications:
Responsible Party: Lawson Health Research Institute
ClinicalTrials.gov Identifier: NCT00377117     History of Changes
Other Study ID Numbers: R-05-470
First Posted: September 15, 2006    Key Record Dates
Last Update Posted: November 6, 2018
Last Verified: November 2018

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Diabetes Mellitus
Schizophrenia
Psychotic Disorders
Mental Disorders
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Schizophrenia Spectrum and Other Psychotic Disorders